Glucophage for Treatment of Diabetes - Glucophage Full Prescribing Information
Brand Name: Glucophage
Generic Name: metformin hydrochloride
Dosage Form: extended-release tablets
Glucohage, metformin hydrochloride, patient information (in plain English)
Glucophage® (metformin hydrochloride) Tablets and Glucophage® XR (metformin hydrochloride) Extended-Release Tablets are oral antihyperglycemic drugs used in the management of type 2 diabetes. Metformin hydrochloride (N,N-dimethylimidodicarbonimidic diamide hydrochloride) is not chemically or pharmacologically related to any other classes of oral antihyperglycemic agents. The structural formula is as shown:
Metformin hydrochloride is a white to off-white crystalline compound with a molecular formula of C4H11N5 - HCl and a molecular weight of 165.63. Metformin hydrochloride is freely soluble in water and is practically insoluble in acetone, ether, and chloroform. The pKa of metformin is 12.4. The pH of a 1% aqueous solution of metformin hydrochloride is 6.68.
Glucophage tablets contain 500 mg, 850 mg, or 1000 mg of metformin hydrochloride. Each tablet contains the inactive ingredients povidone and magnesium stearate. In addition, the coating for the 500 mg and 850 mg tablets contains hypromellose and the coating for the 1000 mg tablet contains hypromellose and polyethylene glycol.
Glucophage XR contains 500 mg or 750 mg of metformin hydrochloride as the active ingredient.
Glucophage XR 500 mg tablets contain the inactive ingredients sodium carboxymethyl cellulose, hypromellose, microcrystalline cellulose, and magnesium stearate.
Glucophage XR 750 mg tablets contain the inactive ingredients sodium carboxymethyl cellulose, hypromellose, and magnesium stearate.
System Components and Performance-Glucophage XR comprises a dual hydrophilic polymer matrix system. Metformin hydrochloride is combined with a drug release controlling polymer to form an "inner" phase, which is then incorporated as discrete particles into an "external" phase of a second polymer. After administration, fluid from the gastrointestinal (GI) tract enters the tablet, causing the polymers to hydrate and swell. Drug is released slowly from the dosage form by a process of diffusion through the gel matrix that is essentially independent of pH. The hydrated polymer system is not rigid and is expected to be broken up by normal peristalsis in the GI tract. The biologically inert components of the tablet may occasionally remain intact during GI transit and will be eliminated in the feces as a soft, hydrated mass.
Mechanism of Action
Metformin is an antihyperglycemic agent which improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Its pharmacologic mechanisms of action are different from other classes of oral antihyperglycemic agents. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. Unlike sulfonylureas, metformin does not produce hypoglycemia in either patients with type 2 diabetes or normal subjects (except in special circumstances, see PRECAUTIONS) and does not cause hyperinsulinemia. With metformin therapy, insulin secretion remains unchanged while fasting insulin levels and day-long plasma insulin response may actually decrease.
Absorption and Bioavailability
The absolute bioavailability of a Glucophage 500 mg tablet given under fasting conditions is approximately 50% to 60%. Studies using single oral doses of Glucophage 500 to 1500 mg, and 850 to 2550 mg, indicate that there is a lack of dose proportionality with increasing doses, which is due to decreased absorption rather than an alteration in elimination. Food decreases the extent of and slightly delays the absorption of metformin, as shown by approximately a 40% lower mean peak plasma concentration (Cmax), a 25% lower area under the plasma concentration versus time curve (AUC), and a 35-minute prolongation of time to peak plasma concentration (Tmax) following administration of a single 850 mg tablet of metformin with food, compared to the same tablet strength administered fasting. The clinical relevance of these decreases is unknown.
Following a single oral dose of Glucophage XR, Cmax is achieved with a median value of 7 hours and a range of 4 to 8 hours. Peak plasma levels are approximately 20% lower compared to the same dose of Glucophage, however, the extent of absorption (as measured by AUC) is similar to Glucophage.
At steady state, the AUC and Cmax are less than dose proportional for Glucophage XR within the range of 500 to 2000 mg administered once daily. Peak plasma levels are approximately 0.6, 1.1, 1.4, and 1.8 µg/mL for 500, 1000, 1500, and 2000 mg once-daily doses, respectively. The extent of metformin absorption (as measured by AUC) from Glucophage XR at a 2000 mg once-daily dose is similar to the same total daily dose administered as Glucophage tablets 1000 mg twice daily. After repeated administration of Glucophage XR, metformin did not accumulate in plasma.
Within-subject variability in Cmax and AUC of metformin from Glucophage XR is comparable to that with Glucophage.
Although the extent of metformin absorption (as measured by AUC) from the Glucophage XR tablet increased by approximately 50% when given with food, there was no effect of food on Cmax and Tmax of metformin. Both high and low fat meals had the same effect on the pharmacokinetics of Glucophage XR.
The apparent volume of distribution (V/F) of metformin following single oral doses of Glucophage 850 mg averaged 654 ± 358 L. Metformin is negligibly bound to plasma proteins, in contrast to sulfonylureas, which are more than 90% protein bound. Metformin partitions into erythrocytes, most likely as a function of time. At usual clinical doses and dosing schedules of Glucophage, steady state plasma concentrations of metformin are reached within 24 to 48 hours and are generally
Metabolism and Elimination
Intravenous single-dose studies in normal subjects demonstrate that metformin is excreted unchanged in the urine and does not undergo hepatic metabolism (no metabolites have been identified in humans) nor biliary excretion. Renal clearance (see Table 1) is approximately 3.5 times greater than creatinine clearance, which indicates that tubular secretion is the major route of metformin elimination. Following oral administration, approximately 90% of the absorbed drug is eliminated via the renal route within the first 24 hours, with a plasma elimination half-life of approximately 6.2 hours. In blood, the elimination half-life is approximately 17.6 hours, suggesting that the erythrocyte mass may be a compartment of distribution.
Patients with Type 2 Diabetes
In the presence of normal renal function, there are no differences between single- or multiple-dose pharmacokinetics of metformin between patients with type 2 diabetes and normal subjects (see Table 1), nor is there any accumulation of metformin in either group at usual clinical doses.
The pharmacokinetics of Glucophage XR in patients with type 2 diabetes are comparable to those in healthy normal adults.
In patients with decreased renal function (based on measured creatinine clearance), the plasma and blood half-life of metformin is prolonged and the renal clearance is decreased in proportion to the decrease in creatinine clearance (see Table 1; also see WARNINGS).
No pharmacokinetic studies of metformin have been conducted in patients with hepatic insufficiency.
Limited data from controlled pharmacokinetic studies of Glucophage in healthy elderly subjects suggest that total plasma clearance of metformin is decreased, the half-life is prolonged, and Cmax is increased, compared to healthy young subjects. From these data, it appears that the change in metformin pharmacokinetics with aging is primarily accounted for by a change in renal function (see Table 1). Glucophage (metformin hydrochloride) Tablets and Glucophage XR (metformin hydrochloride) Extended-Release Tablets treatment should not be initiated in patients â‰¥80 years of age unless measurement of creatinine clearance demonstrates that renal function is not reduced (see WARNINGS and DOSAGE AND ADMINISTRATION).
|Subject Groups: Glucophage dosea|
(number of subjects)
|a All doses given fasting except the first 18 doses of the multiple dose studies|
|b Peak plasma concentration|
|c Time to peak plasma concentration|
|d Combined results (average means) of five studies: mean age 32 years (range 23-59 years)|
|e Kinetic study done following dose 19, given fasting|
|f Elderly subjects, mean age 71 years (range 65-81 years)|
|g CLcr = creatinine clearance normalized to body surface area of 1.73 m2|
|Healthy, nondiabetic adults:|
|500 mg single dose (24)||1.03 ( ±0.33)||2.75 ( ±0.81)||600 ( ±132)|
|850 mg single dose (74)d||1.60 ( ±0.38)||2.64 ( ±0.82)||552 ( ±139)|
|850 mg three times daily for 19 dosese (9)||2.01 ( ±0.42)||1.79 ( ±0.94)||642 ( ±173)|
|Adults with type 2 diabetes:|
|850 mg single dose (23)||1.48 ( ±0.5)||3.32 ( ±1.08)||491 ( ±138)|
|850 mg three times daily for 19 dosese (9)||1.90 ( ±0.62)||2.01 ( ±1.22)||550 ( ±160)|
|Elderlyf, healthy nondiabetic adults:|
|850 mg single dose (12)||2.45 ( ±0.70)||2.71 ( ±1.05)||412 ( ±98)|
|850 mg single dose|
|Mild (CLcrg 61-90 mL/min) (5)||1.86 ( ±0.52)||3.20 ( ±0.45)||384 ( ±122)|
|Moderate (CLcr 31-60 mL/min) (4)||4.12 ( ±1.83)||3.75 ( ±0.50)||108 ( ±57)|
|Severe (CLcr 10-30 mL/min) (6)||3.93 ( ±0.92)||4.01 ( ±1.10)||130 ( ±90|
After administration of a single oral Glucophage 500 mg tablet with food, geometric mean metformin Cmax and AUC differed less than 5% between pediatric type 2 diabetic patients (12-16 years of age) and gender- and weight-matched healthy adults (20-45 years of age), all with normal renal function
Metformin pharmacokinetic parameters did not differ significantly between normal subjects and patients with type 2 diabetes when analyzed according to gender (males = 19, females = 16). Similarly, in controlled clinical studies in patients with type 2 diabetes, the antihyperglycemic effect of Glucophage was comparable in males and females.
No studies of metformin pharmacokinetic parameters according to race have been performed. In controlled clinical studies of Glucophage in patients with type 2 diabetes, the antihyperglycemic effect was comparable in whites (n=249), blacks (n=51), and Hispanics (n=24).
In a double-blind, placebo-controlled, multicenter US clinical trial involving obese patients with type 2 diabetes whose hyperglycemia was not adequately controlled with dietary management alone (baseline fasting plasma glucose [FPG] of approximately 240 mg/dL), treatment with Glucophage (up to 2550 mg/day) for 29 weeks resulted in significant mean net reductions in fasting and postprandial plasma glucose (PPG) and hemoglobin A1c (HbA1c) of 59 mg/dL, 83 mg/dL, and 1.8%, respectively, compared to the placebo group (see Table 2).
|* All patients on diet therapy at Baseline||** Not statistically significant|
|FPG (mg/dL) |
Change at FINAL VISIT
|Hemoglobin A1c (%) |
Change at FINAL VISIT
|Body Weight (lbs) |
Change at FINAL VISIT
A 29-week, double-blind, placebo-controlled study of Glucophage and glyburide, alone and in combination, was conducted in obese patients with type 2 diabetes who had failed to achieve adequate glycemic control while on maximum doses of glyburide (baseline FPG of approximately 250 mg/dL) (see Table 3). Patients randomized to the combination arm started therapy with Glucophage 500 mg and glyburide 20 mg. At the end of each week of the first 4 weeks of the trial, these patients had their dosages of Glucophage increased by 500 mg if they had failed to reach target fasting plasma glucose. After week 4, such dosage adjustments were made monthly, although no patient was allowed to exceed Glucophage 2500 mg. Patients in the Glucophage only arm (metformin plus placebo) followed the same titration schedule. At the end of the trial, approximately 70% of the patients in the combination group were taking Glucophage 2000 mg/glyburide 20 mg or Glucophage 2500 mg/glyburide 20 mg. Patients randomized to continue on glyburide experienced worsening of glycemic control, with mean increases in FPG, PPG, and HbA1c of 14 mg/dL, 3 mg/dL, and 0.2%, respectively. In contrast, those randomized to Glucophage (up to 2500 mg/day) experienced a slight improvement, with mean reductions in FPG, PPG, and HbA1c of 1 mg/dL, 6 mg/dL, and 0.4%, respectively. The combination of Glucophage and glyburide was effective in reducing FPG, PPG, and HbA1c levels by 63 mg/dL, 65 mg/dL, and 1.7%, respectively. Compared to results of glyburide treatment alone, the net differences with combination treatment were -77 mg/dL, -68 mg/dL, and -1.9%, respectively (see Table 3).
Table 3: Combined Glucophage/Glyburide (Comb) vs Glyburide (Glyb) or Glucophage (GLU) Monotherapy: Summary of Mean Changes from Baseline* in Fasting Plasma Glucose, HbA1c, and Body Weight, at Final Visit (29-week study)
|* All patients on glyburide, 20 mg/day, at Baseline||** Not statistically significant|
|Fasting Plasma Glucose (mg/dL)|
Change at FINAL VISIT
|Hemoglobin A1c (%)|
Change at FINAL VISIT
|Body Weight (lbs)|
Change at FINAL VISIT
The magnitude of the decline in fasting blood glucose concentration following the institution of Glucophage (metformin hydrochloride) Tablets therapy was proportional to the level of fasting hyperglycemia. Patients with type 2 diabetes with higher fasting glucose concentrations experienced greater declines in plasma glucose and glycosylated hemoglobin.
In clinical studies, Glucophage, alone or in combination with a sulfonylurea, lowered mean fasting serum triglycerides, total cholesterol, and LDL cholesterol levels, and had no adverse effects on other lipid levels (see Table 4).
|Glucophage vs Placebo||Combined Glucophage/Glyburide|
|Total Cholesterol (mg/dL)|
Mean % Change at FINAL VISIT
|Total Triglycerides (mg/dL)|
Mean % Change at FINAL VISIT
Mean % Change at FINAL VISIT
Mean % Change at FINAL VISIT
A 24-week, double-blind, placebo-controlled study of Glucophage plus insulin versus insulin plus placebo was conducted in patients with type 2 diabetes who failed to achieve adequate glycemic control on insulin alone (see Table 5). Patients randomized to receive Glucophage plus insulin achieved a reduction in HbA1c of 2.10%, compared to a 1.56% reduction in HbA1c achieved by insulin plus placebo. The improvement in glycemic control was achieved at the final study visit with 16% less insulin, 93.0 U/day vs 110.6 U/day, Glucophage plus insulin versus insulin plus placebo, respectively, p=0.04.
Table 5: Combined Glucophage/Insulin vs Placebo/Insulin Summary of Mean Changes from Baseline in HbA1c and Daily Insulin Dose
Mean ± SE
|a Statistically significant using analysis of covariance with baseline as covariate (p=0.04) |
Not significant using analysis of variance (values shown in table)
|b Statistically significant for insulin (p=0.04)|
|Hemoglobin A1c (%)|
Change at FINAL VISIT
-0.54 ± 0.43a
|Insulin Dose (U/day)|
Change at FINAL VISIT
-16.08 ± 7.77b
A second double-blind, placebo-controlled study (n=51), with 16 weeks of randomized treatment, demonstrated that in patients with type 2 diabetes controlled on insulin for 8 weeks with an average HbA1c of 7.46 ± 0.97%, the addition of Glucophage maintained similar glycemic control (HbA1c 7.15 ± 0.61 vs 6.97 ± 0.62 for Glucophage plus insulin and placebo plus insulin, respectively) with 19% less insulin versus baseline (reduction of 23.68 ± 30.22 vs an increase of 0.43 ± 25.20 units for Glucophage plus insulin and placebo plus insulin, p<0.01). In addition, this study demonstrated that the combination of Glucophage plus insulin resulted in reduction in body weight of 3.11 ± 4.30 lbs, compared to an increase of 1.30 ± 6.08 lbs for placebo plus insulin, p=0.01.
A 24-week, double-blind, placebo-controlled study of Glucophage XR, taken once daily with the evening meal, was conducted in patients with type 2 diabetes who had failed to achieve glycemic control with diet and exercise (HbA1c 7.0%-10.0%, FPG 126-270 mg/dL). Patients entering the study had a mean baseline HbA1c of 8.0% and a mean baseline FPG of 176 mg/dL. After 12 weeks treatment, mean HbA1c had increased from baseline by 0.1% and mean FPG decreased from baseline by 2 mg/dL in the placebo group, compared with a decrease in mean HbA1c of 0.6% and a decrease in mean FPG of 23 mg/dL in patients treated with Glucophage XR 1000 mg once daily. Subsequently, the treatment dose was increased to 1500 mg once daily if HbA1c wasâ‰¥7.0% but <8.0% (patients with HbA1c â‰¥8.0% were discontinued from the study). At the final visit (24-week), mean HbA1c had increased 0.2% from baseline in placebo patients and decreased 0.6% with Glucophage XR.
A 16-week, double-blind, placebo-controlled, dose-response study of Glucophage XR, taken once daily with the evening meal or twice daily with meals, was conducted in patients with type 2 diabetes who had failed to achieve glycemic control with diet and exercise (HbA1c 7.0%-11.0%, FPG 126-280 mg/dL). Changes in glycemic control and body weight are shown in Table 6.
Table 6: Summary of Mean Changes from Baseline* in HbA1c, Fasting Plasma Glucose, and Body Weight at Final Visit (16-week study)
|* All patients on diet therapy at Baseline|
|a All comparisons versus Placebo|
|** Not statistically significant|
|Hemoglobin A1c (%)||(n=115)||(n=115)||(n=111)||(n=125)||(n=112)||(n=111)|
|Change at FINAL VISIT||-0.4||-0.6||-0.9||-0.8||-1.1||0.1|
|Change at FINAL VISIT||-15.2||-19.3||-28.5||-29.9||-33.6||7.6|
|Body Weight (lbs)||(n=125)||(n=119)||(n=117)||(n=131)||(n=119)||(n=113)|
|Change at FINAL VISIT||-1.3||-1.3||-0.7||-1.5||-2.2||-1.8|
Compared with placebo, improvement in glycemic control was seen at all dose levels of Glucophage XR (metformin hydrochloride) Extended-Release Tablets and treatment was not associated with any significant change in weight (see DOSAGE AND ADMINISTRATION for dosing recommendations for Glucophage and Glucophage XR).
A 24-week, double-blind, randomized study of Glucophage XR, taken once daily with the evening meal, and Glucophage (metformin hydrochloride) Tablets, taken twice daily (with breakfast and evening meal), was conducted in patients with type 2 diabetes who had been treated with Glucophage 500 mg twice daily for at least 8 weeks prior to study entry. The Glucophage dose had not necessarily been titrated to achieve a specific level of glycemic control prior to study entry. Patients qualified for the study if HbA1c wasâ‰¤8.5% and FPG was â‰¤200 mg/dL. Changes in glycemic control and body weight are shown in Table 7.
Table 7: Summary of Mean Changes from Baseline* in HbA1c, Fasting Plasma Glucose, and Body Weight at Week 12 and at Final Visit (24-week study)
|* All patients on Glucophage 500 mg twice daily at Baseline|
|Hemoglobin A1c (%)||(n=67)||(n=72)||(n=66)|
|Change at 12 Weeks||0.14||0.23||0.04|
|(95% CI)||(-0.03, 0.31)||(0.10, 0.36)||(-0.08, 0.15)|
|Change at FINAL VISIT||0.14a||0.27||0.13|
|(95% CI)||(-0.04, 0.31)||(0.11, 0.43)||(-0.02, 0.28)|
|Change at 12 Weeks||12.9||9.5||3.7|
|(95% CI)||(6.5, 19.4)||(4.4, 14.6)||(-0.4, 7.8)|
|Change at FINAL VISIT||14.0||11.5||7.6|
|(95% CI)||(7.0, 21.0)||(4.4, 18.6)||(1.0, 14.2)|
|Body Weight (lbs)||(n=71)||(n=74)||(n=71)|
|Change at 12 Weeks||0.4||0.9||0.7|
|(95% CI)||(-0.4, 1.5)||(0.0, 2.0)||(-0.4, 1.8)|
|Change at FINAL VISIT||0.9||1.1||0.9|
|(95% CI)||(-0.4, 2.2)||(-0.2, 2.4)||(-0.4, 2.0)|
After 12 weeks of treatment, there was an increase in mean HbA1c in all groups; in the Glucophage XR 1000 mg group, the increase from baseline of 0.23% was statistically significant (see DOSAGE AND ADMINISTRATION).
Changes in lipid parameters in the previously described placebo-controlled dose-response study of Glucophage XR are shown in Table 8.
Table 8: Summary of Mean Percent Changes from Baseline* in Major Lipid Variables at Final Visit (16-week study)
|* All patients on diet therapy at Baseline|
|Total Cholesterol (mg/dL)||(n=120)||(n=113)||(n=110)||(n=126)||(n=117)||(n=110)|
|Mean % Change at FINAL VISIT||1.0%||1.7%||0.7%||-1.6%||-2.6%||2.6%|
|Total Triglycerides (mg/dL)||(n=120)||(n=113)||(n=110)||(n=126)||(n=117)||(n=110)|
|Mean % Change at FINAL VISIT||14.5%||9.4%||15.1%||14.9%||9.4%||10.9%|
|Mean % Change at FINAL VISIT||-1.4%||-1.6%||-3.5%||-3.3%||-5.5%||3.2%|
|Mean % Change at FINAL VISIT||6.2%||8.6%||5.5%||6.1%||7.1%||5.8%|
Changes in lipid parameters in the previously described study of Glucophage and Glucophage XR are shown in Table 9.
Table 9: Summary of Mean Percent Changes from Baseline* in Major Lipid Variables at Final Visit (24-week study)
|* All patients on Glucophage 500 mg twice daily at Baseline|
|Total Cholesterol (mg/dL)||(n=68)||(n=70)||(n=66)|
|Mean % Change at FINAL VISIT||0.1%||1.3%||0.1%|
|Total Triglycerides (mg/dL)||(n=68)||(n=70)||(n=66)|
|Mean % Change at FINAL VISIT||6.3%||25.3%||33.4%|
|Mean % Change at FINAL VISIT||âˆ’1.3%||âˆ’3.3%||âˆ’3.7%|
|Mean % Change at FINAL VISIT||4.8%||1.0%||-2.1%|
Pediatric Clinical Studies
In a double-blind, placebo-controlled study in pediatric patients aged 10 to 16 years with type 2 diabetes (mean FPG 182.2 mg/dL), treatment with Glucophage (up to 2000 mg/day) for up to 16 weeks (mean duration of treatment 11 weeks) resulted in a significant mean net reduction in FPG of 64.3 mg/dL, compared with placebo (see Table 10).
Table 10: Glucophage vs Placebo (Pediatricsa) Summary of Mean Changes from Baseline* in Plasma Glucose and Body Weight at Final Visit
|a Pediatric patients mean age 13.8 years (range 10-16 years)|
|* All patients on diet therapy at Baseline|
|** Not statistically significant|
Change at FINAL VISIT
|Body Weight (lbs)||(n=39)||(n=38)|
Change at FINAL VISIT
Glucophage (metformin hydrochloride) Tablets is indicated as an adjunct to diet and exercise to improve glycemic control in adults and children with type 2 diabetes mellitus.
Glucophage XR (metformin hydrochloride) Extended-Release Tablets is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Glucophage and Glucophage XR are contraindicated in patients with:
Renal disease or renal dysfunction (e.g., as suggested by serum creatinine levels â‰¥1.5 mg/dL [males], â‰¥1.4 mg/dL [females] or abnormal creatinine clearance) which may also result from conditions such as cardiovascular collapse (shock), acute myocardial infarction, and septicemia (see WARNINGS and PRECAUTIONS).
Known hypersensitivity to metformin hydrochloride.
Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. Diabetic ketoacidosis should be treated with insulin.
Glucophage and Glucophage XR should be temporarily discontinued in patients undergoing radiologic studies involving intravascular administration of iodinated contrast materials, because use of such products may result in acute alteration of renal function. (See also PRECAUTIONS.)
Lactic acidosis is a rare, but serious, metabolic complication that can occur due to metformin accumulation during treatment with Glucophage or Glucophage XR; when it occurs, it is fatal in approximately 50% of cases. Lactic acidosis may also occur in association with a number of pathophysiologic conditions, including diabetes mellitus, and whenever there is significant tissue hypoperfusion and hypoxemia. Lactic acidosis is characterized by elevated blood lactate levels (>5 mmol/L), decreased blood pH, electrolyte disturbances with an increased anion gap, and an increased lactate/pyruvate ratio. When metformin is implicated as the cause of lactic acidosis, metformin plasma levels >5 µg/mL are generally found.
The reported incidence of lactic acidosis in patients receiving metformin hydrochloride is very low (approximately 0.03 cases/1000 patient-years, with approximately 0.015 fatal cases/1000 patient-years). In more than 20,000 patient-years exposure to metformin in clinical trials, there were no reports of lactic acidosis. Reported cases have occurred primarily in diabetic patients with significant renal insufficiency, including both intrinsic renal disease and renal hypoperfusion, often in the setting of multiple concomitant medical/surgical problems and multiple concomitant medications. Patients with congestive heart failure requiring pharmacologic management, in particular those with unstable or acute congestive heart failure who are at risk of hypoperfusion and hypoxemia, are at increased risk of lactic acidosis. The risk of lactic acidosis increases with the degree of renal dysfunction and the patient's age. The risk of lactic acidosis may, therefore, be significantly decreased by regular monitoring of renal function in patients taking Glucophage or Glucophage XR and by use of the minimum effective dose of Glucophage or Glucophage XR. In particular, treatment of the elderly should be accompanied by careful monitoring of renal function. Glucophage or Glucophage XR treatment should not be initiated in patients â‰¥80 years of age unless measurement of creatinine clearance demonstrates that renal function is not reduced, as these patients are more susceptible to developing lactic acidosis. In addition, Glucophage and Glucophage XR should be promptly withheld in the presence of any condition associated with hypoxemia, dehydration, or sepsis. Because impaired hepatic function may significantly limit the ability to clear lactate, Glucophage and Glucophage XR should generally be avoided in patients with clinical or laboratory evidence of hepatic disease. Patients should be cautioned against excessive alcohol intake, either acute or chronic, when taking Glucophage or Glucophage XR, since alcohol potentiates the effects of metformin hydrochloride on lactate metabolism. In addition, Glucophage and Glucophage XR should be temporarily discontinued prior to any intravascular radiocontrast study and for any surgical procedure (see also PRECAUTIONS).
The onset of lactic acidosis often is subtle, and accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, increasing somnolence, and nonspecific abdominal distress. There may be associated hypothermia, hypotension, and resistant bradyarrhythmias with more marked acidosis. The patient and the patient's physician must be aware of the possible importance of such symptoms and the patient should be instructed to notify the physician immediately if they occur (see also PRECAUTIONS). Glucophage and Glucophage XR should be withdrawn until the situation is clarified. Serum electrolytes, ketones, blood glucose, and if indicated, blood pH, lactate levels, and even blood metformin levels may be useful. Once a patient is stabilized on any dose level of Glucophage or Glucophage XR, gastrointestinal symptoms, which are common during initiation of therapy, are unlikely to be drug related. Later occurrence of gastrointestinal symptoms could be due to lactic acidosis or other serious disease.
Levels of fasting venous plasma lactate above the upper limit of normal but less than 5 mmol/L in patients taking Glucophage or Glucophage XR do not necessarily indicate impending lactic acidosis and may be explainable by other mechanisms, such as poorly controlled diabetes or obesity, vigorous physical activity, or technical problems in sample handling. (See also PRECAUTIONS.)
Lactic acidosis should be suspected in any diabetic patient with metabolic acidosis lacking evidence of ketoacidosis (ketonuria and ketonemia).
Lactic acidosis is a medical emergency that must be treated in a hospital setting. In a patient with lactic acidosis who is taking Glucophage or Glucophage XR, the drug should be discontinued immediately and general supportive measures promptly instituted. Because metformin hydrochloride is dialyzable (with a clearance of up to 170 mL/min under good hemodynamic conditions), prompt hemodialysis is recommended to correct the acidosis and remove the accumulated metformin. Such management often results in prompt reversal of symptoms and recovery. (See also CONTRAINDICATIONS and PRECAUTIONS.)
Macrovascular Outcomes—There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with Glucophage or Glucophage XR or any other antidiabetic drug.
Monitoring of renal function—Metformin is known to be substantially excreted by the kidney, and the risk of metformin accumulation and lactic acidosis increases with the degree of impairment of renal function. Thus, patients with serum creatinine levels above the upper limit of normal for their age should not receive Glucophage or Glucophage XR. In patients with advanced age, Glucophage and Glucophage XR should be carefully titrated to establish the minimum dose for adequate glycemic effect, because aging is associated with reduced renal function. In elderly patients, particularly those â‰¥80 years of age, renal function should be monitored regularly and, generally, Glucophage and Glucophage XR should not be titrated to the maximum dose (see WARNINGS and DOSAGE AND ADMINISTRATION).
Before initiation of Glucophage or Glucophage XR therapy and at least annually thereafter, renal function should be assessed and verified as normal. In patients in whom development of renal dysfunction is anticipated, renal function should be assessed more frequently and Glucophage or Glucophage XR discontinued if evidence of renal impairment is present.
Use of concomitant medications that may affect renal function or metformin disposition—Concomitant medication(s) that may affect renal function or result in significant hemodynamic change or may interfere with the disposition of metformin, such as cationic drugs that are eliminated by renal tubular secretion (see PRECAUTIONS: Drug Interactions), should be used with caution.
Radiologic studies involving the use of intravascular iodinated contrast materials (for example, intravenous urogram, intravenous cholangiography, angiography, and computed tomography (CT) scans with intravascular contrast materials)—Intravascular contrast studies with iodinated materials can lead to acute alteration of renal function and have been associated with lactic acidosis in patients receiving metformin (see CONTRAINDICATIONS). Therefore, in patients in whom any such study is planned, Glucophage or Glucophage XR should be temporarily discontinued at the time of or prior to the procedure, and withheld for 48 hours subsequent to the procedure and reinstituted only after renal function has been re-evaluated and found to be normal.
Hypoxic states—Cardiovascular collapse (shock) from whatever cause, acute congestive heart failure, acute myocardial infarction and other conditions characterized by hypoxemia have been associated with lactic acidosis and may also cause prerenal azotemia. When such events occur in patients on Glucophage or Glucophage XR therapy, the drug should be promptly discontinued.
Surgical procedures—Glucophage or Glucophage XR therapy should be temporarily suspended for any surgical procedure (except minor procedures not associated with restricted intake of food and fluids) and should not be restarted until the patient's oral intake has resumed and renal function has been evaluated as normal.
Alcohol intake—Alcohol is known to potentiate the effect of metformin on lactate metabolism. Patients, therefore, should be warned against excessive alcohol intake, acute or chronic, while receiving Glucophage or Glucophage XR.
Impaired hepatic function—Since impaired hepatic function has been associated with some cases of lactic acidosis, Glucophage and Glucophage XR should generally be avoided in patients with clinical or laboratory evidence of hepatic disease.
Vitamin B12 levels—In controlled clinical trials of Glucophage of 29 weeks duration, a decrease to subnormal levels of previously normal serum vitamin B12 levels, without clinical manifestations, was observed in approximately 7% of patients. Such decrease, possibly due to interference with B12 absorption from the B12-intrinsic factor complex, is, however, very rarely associated with anemia and appears to be rapidly reversible with discontinuation of Glucophage or vitamin B12 supplementation. Measurement of hematologic parameters on an annual basis is advised in patients on Glucophage or Glucophage XR and any apparent abnormalities should be appropriately investigated and managed (see PRECAUTIONS: Laboratory Tests).
Certain individuals (those with inadequate vitamin B12 or calcium intake or absorption) appear to be predisposed to developing subnormal vitamin B12 levels. In these patients, routine serum vitamin B12 measurements at 2- to 3-year intervals may be useful.
Change in clinical status of patients with previously controlled type 2 diabetes—A patient with type 2 diabetes previously well controlled on Glucophage or Glucophage XR who develops laboratory abnormalities or clinical illness (especially vague and poorly defined illness) should be evaluated promptly for evidence of ketoacidosis or lactic acidosis. Evaluation should include serum electrolytes and ketones, blood glucose and, if indicated, blood pH, lactate, pyruvate, and metformin levels. If acidosis of either form occurs, Glucophage or Glucophage XR must be stopped immediately and other appropriate corrective measures initiated (see also WARNINGS).
Hypoglycemia—Hypoglycemia does not occur in patients receiving Glucophage or Glucophage XR alone under usual circumstances of use, but could occur when caloric intake is deficient, when strenuous exercise is not compensated by caloric supplementation, or during concomitant use with other glucose-lowering agents (such as sulfonylureas and insulin) or ethanol.
Elderly, debilitated, or malnourished patients, and those with adrenal or pituitary insufficiency or alcohol intoxication are particularly susceptible to hypoglycemic effects. Hypoglycemia may be difficult to recognize in the elderly, and in people who are taking beta-adrenergic blocking drugs.
Loss of control of blood glucose—When a patient stabilized on any diabetic regimen is exposed to stress such as fever, trauma, infection, or surgery, a temporary loss of glycemic control may occur. At such times, it may be necessary to withhold Glucophage or Glucophage XR and temporarily administer insulin. Glucophage or Glucophage XR may be reinstituted after the acute episode is resolved.
The effectiveness of oral antidiabetic drugs in lowering blood glucose to a targeted level decreases in many patients over a period of time. This phenomenon, which may be due to progression of the underlying disease or to diminished responsiveness to the drug, is known as secondary failure, to distinguish it from primary failure in which the drug is ineffective during initial therapy. Should secondary failure occur with either Glucophage or Glucophage XR or sulfonylurea monotherapy, combined therapy with Glucophage or Glucophage XR and sulfonylurea may result in a response. Should secondary failure occur with combined Glucophage/sulfonylurea therapy or Glucophage XR/sulfonylurea therapy, it may be necessary to consider therapeutic alternatives including initiation of insulin therapy.
Information for Patients
Patients should be informed of the potential risks and benefits of Glucophage or Glucophage XR and of alternative modes of therapy. They should also be informed about the importance of adherence to dietary instructions, of a regular exercise program, and of regular testing of blood glucose, glycosylated hemoglobin, renal function, and hematologic parameters.
The risks of lactic acidosis, its symptoms, and conditions that predispose to its development, as noted in the WARNINGS and PRECAUTIONS sections, should be explained to patients. Patients should be advised to discontinue Glucophage or Glucophage XR immediately and to promptly notify their health practitioner if unexplained hyperventilation, myalgia, malaise, unusual somnolence, or other nonspecific symptoms occur. Once a patient is stabilized on any dose level of Glucophage or Glucophage XR, gastrointestinal symptoms, which are common during initiation of metformin therapy, are unlikely to be drug related. Later occurrence of gastrointestinal symptoms could be due to lactic acidosis or other serious disease.
Patients should be counselled against excessive alcohol intake, either acute or chronic, while receiving Glucophage or Glucophage XR.
Glucophage or Glucophage XR alone does not usually cause hypoglycemia, although it may occur when Glucophage or Glucophage XR is used in conjunction with oral sulfonylureas and insulin. When initiating combination therapy, the risks of hypoglycemia, its symptoms and treatment, and conditions that predispose to its development should be explained to patients and responsible family members.
Patients should be informed that Glucophage XR must be swallowed whole and not crushed or chewed, and that the inactive ingredients may occasionally be eliminated in the feces as a soft mass that may resemble the original tablet.
Response to all diabetic therapies should be monitored by periodic measurements of fasting blood glucose and glycosylated hemoglobin levels, with a goal of decreasing these levels toward the normal range. During initial dose titration, fasting glucose can be used to determine the therapeutic response. Thereafter, both glucose and glycosylated hemoglobin should be monitored. Measurements of glycosylated hemoglobin may be especially useful for evaluating long-term control (see also DOSAGE AND ADMINISTRATION).
Initial and periodic monitoring of hematologic parameters (e.g., hemoglobin/hematocrit and red blood cell indices) and renal function (serum creatinine) should be performed, at least on an annual basis. While megaloblasticanemia has rarely been seen with Glucophage therapy, if this is suspected, vitamin B12 deficiency should be excluded.
Drug Interactions (Clinical Evaluation of Drug Interactions Conducted with Glucophage)
Glyburide—In a single-dose interaction study in type 2 diabetes patients, coadministration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. Decreases in glyburide AUC and Cmax were observed, but were highly variable. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION: Concomitant Glucophage or Glucophage XR and Oral Sulfonylurea Therapy in Adult Patients).
Furosemide—A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by coadministration. Furosemide increased the metformin plasma and blood Cmax by 22% and blood AUC by 15%, without any significant change in metformin renal clearance. When administered with metformin, the Cmax and AUC of furosemide were 31% and 12% smaller, respectively, than when administered alone, and the terminal half-life was decreased by 32%, without any significant change in furosemide renal clearance. No information is available about the interaction of metformin and furosemide when coadministered chronically.
Nifedipine—A single-dose, metformin-nifedipine drug interaction study in normal healthy volunteers demonstrated that coadministration of nifedipine increased plasma metformin Cmax and AUC by 20% and 9%, respectively, and increased the amount excreted in the urine. Tmax and half-life were unaffected. Nifedipine appears to enhance the absorption of metformin. Metformin had minimal effects on nifedipine.
Cationic drugs—Cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, or vancomycin) that are eliminated by renal tubular secretion theoretically have the potential for interaction with metformin by competing for common renal tubular transport systems. Such interaction between metformin and oral cimetidine has been observed in normal healthy volunteers in both single- and multiple-dose, metformin-cimetidine drug interaction studies, with a 60% increase in peak metformin plasma and whole blood concentrations and a 40% increase in plasma and whole blood metformin AUC. There was no change in elimination half-life in the single-dose study. Metformin had no effect on cimetidine pharmacokinetics. Although such interactions remain theoretical (except for cimetidine), careful patient monitoring and dose adjustment of Glucophage or Glucophage XR and/or the interfering drug is recommended in patients who are taking cationic medications that are excreted via the proximal renal tubular secretory system.
Other—Certain drugs tend to produce hyperglycemia and may lead to loss of glycemic control. These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glucophage or Glucophage XR, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glucophage or Glucophage XR, the patient should be observed closely for hypoglycemia.
In healthy volunteers, the pharmacokinetics of metformin and propranolol, and metformin and ibuprofen were not affected when coadministered in single-dose interaction studies.
Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid, as compared to the sulfonylureas, which are extensively bound to serum proteins.
Carcinogenesis, Mutagenesis, Impairment of Fertility
Long-term carcinogenicity studies have been performed in rats (dosing duration of 104 weeks) and mice (dosing duration of 91 weeks) at doses up to and including 900 mg/kg/day and 1500 mg/kg/day, respectively. These doses are both approximately 4 times the maximum recommended human daily dose of 2000 mg based on body surface area comparisons. No evidence of carcinogenicity with metformin was found in either male or female mice. Similarly, there was no tumorigenic potential observed with metformin in male rats. There was, however, an increased incidence of benign stromal uterine polyps in female rats treated with 900 mg/kg/day.
There was no evidence of a mutagenic potential of metformin in the following in vitro tests: Ames test (S. typhimurium), gene mutation test (mouse lymphoma cells), or chromosomal aberrations test (human lymphocytes). Results in the in vivo mouse micronucleus test were also negative.
Fertility of male or female rats was unaffected by metformin when administered at doses as high as 600 mg/kg/day, which is approximately 3 times the maximum recommended human daily dose based on body surface area comparisons.
Teratogenic Effects: Pregnancy Category B
Recent information strongly suggests that abnormal blood glucose levels during pregnancy are associated with a higher incidence of congenital abnormalities. Most experts recommend that insulin be used during pregnancy to maintain blood glucose levels as close to normal as possible. Because animal reproduction studies are not always predictive of human response, Glucophage and Glucophage XR should not be used during pregnancy unless clearly needed.
There are no adequate and well-controlled studies in pregnant women with Glucophage or Glucophage XR. Metformin was not teratogenic in rats and rabbits at doses up to 600 mg/kg/day. This represents an exposure of about 2 and 6 times the maximum recommended human daily dose of 2000 mg based on body surface area comparisons for rats and rabbits, respectively. Determination of fetal concentrations demonstrated a partial placental barrier to metformin.
Studies in lactating rats show that metformin is excreted into milk and reaches levels comparable to those in plasma. Similar studies have not been conducted in nursing mothers. Because the potential for hypoglycemia in nursing infants may exist, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. If Glucophage or Glucophage XR is discontinued, and if diet alone is inadequate for controlling blood glucose, insulin therapy should be considered.
The safety and effectiveness of Glucophage for the treatment of type 2 diabetes have been established in pediatric patients ages 10 to 16 years (studies have not been conducted in pediatric patients below the age of 10 years). Use of Glucophage in this age group is supported by evidence from adequate and well-controlled studies of Glucophage in adults with additional data from a controlled clinical study in pediatric patients ages 10 to 16 years with type 2 diabetes, which demonstrated a similar response in glycemic control to that seen in adults. (See CLINICAL PHARMACOLOGY: Pediatric Clinical Studies.) In this study, adverse effects were similar to those described in adults. (See ADVERSE REACTIONS: Pediatric Patients.) A maximum daily dose of 2000 mg is recommended. (See DOSAGE AND ADMINISTRATION: Recommended Dosing Schedule: Pediatrics.)
Safety and effectiveness of Glucophage XR in pediatric patients have not been established.
Controlled clinical studies of Glucophage and Glucophage XR did not include sufficient numbers of elderly patients to determine whether they respond differently from younger patients, although other reported clinical experience has not identified differences in responses between the elderly and younger patients. Metformin is known to be substantially excreted by the kidney and because the risk of serious adverse reactions to the drug is greater in patients with impaired renal function, Glucophage and Glucophage XR should only be used in patients with normal renal function (see CONTRAINDICATIONS, WARNINGS, and CLINICAL PHARMACOLOGY: Pharmacokinetics). Because aging is associated with reduced renal function, Glucophage or Glucophage XR should be used with caution as age increases. Care should be taken in dose selection and should be based on careful and regular monitoring of renal function. Generally, elderly patients should not be titrated to the maximum dose of Glucophage or Glucophage XR (see also WARNINGS and DOSAGE AND ADMINISTRATION).
In a US double-blind clinical study of Glucophage in patients with type 2 diabetes, a total of 141 patients received Glucophage therapy (up to 2550 mg per day) and 145 patients received placebo. Adverse reactions reported in greater than 5% of the Glucophage patients, and that were more common in Glucophage- than placebo-treated patients, are listed in Table 11.
Table 11: Most Common Adverse Reactions (>5.0 Percent) in a Placebo-Controlled Clinical Study of Glucophage Monotherapy*
|% of Patients|
|* Reactions that were more common in Glucophage- than placebo-treated patients.|
Diarrhea led to discontinuation of study medication in 6% of patients treated with Glucophage. Additionally, the following adverse reactions were reported in â‰¥1.0% to â‰¤5.0% of Glucophage patients and were more commonly reported with Glucophage than placebo: abnormal stools, hypoglycemia, myalgia, lightheaded, dyspnea, nail disorder, rash, sweating increased, taste disorder, chest discomfort, chills, flu syndrome, flushing, palpitation.
In worldwide clinical trials over 900 patients with type 2 diabetes have been treated with Glucophage XR in placebo- and active-controlled studies. In placebo-controlled trials, 781 patients were administered Glucophage XR and 195 patients received placebo. Adverse reactions reported in greater than 5% of the Glucophage XR patients, and that were more common in Glucophage XR- than placebo-treated patients, are listed in Table 12.
Table 12: Most Common Adverse Reactions (>5.0 Percent) in Placebo-Controlled Studies of Glucophage XR*
|Adverse Reaction||Glucophage XR|
|% of Patients|
|* Reactions that were more common in Glucophage XR- than placebo-treated patients.|
Diarrhea led to discontinuation of study medication in 0.6% of patients treated with Glucophage XR. Additionally, the following adverse reactions were reported in â‰¥1.0% to â‰¤5.0% of Glucophage XR patients and were more commonly reported with Glucophage XR than placebo: abdominal pain, constipation, distention abdomen, dyspepsia/heartburn, flatulence, dizziness, headache, upper respiratory infection, taste disturbance.
In clinical trials with Glucophage in pediatric patients with type 2 diabetes, the profile of adverse reactions was similar to that observed in adults.
Overdose of metformin hydrochloride has occurred, including ingestion of amounts greater than 50 grams. Hypoglycemia was reported in approximately 10% of cases, but no causal association with metformin hydrochloride has been established. Lactic acidosis has been reported in approximately 32% of metformin overdose cases (see WARNINGS). Metformin is dialyzable with a clearance of up to 170 mL/min under good hemodynamic conditions. Therefore, hemodialysis may be useful for removal of accumulated drug from patients in whom metformin overdosage is suspected.
There is no fixed dosage regimen for the management of hyperglycemia in patients with type 2 diabetes with Glucophage or Glucophage XR or any other pharmacologic agent. Dosage of Glucophage or Glucophage XR must be individualized on the basis of both effectiveness and tolerance, while not exceeding the maximum recommended daily doses. The maximum recommended daily dose of Glucophage is 2550 mg in adults and 2000 mg in pediatric patients (10-16 years of age); the maximum recommended daily dose of Glucophage XR in adults is 2000 mg.
Glucophage should be given in divided doses with meals while Glucophage XR should generally be given once daily with the evening meal. Glucophage or Glucophage XR should be started at a low dose, with gradual dose escalation, both to reduce gastrointestinal side effects and to permit identification of the minimum dose required for adequate glycemic control of the patient.
During treatment initiation and dose titration (see Recommended Dosing Schedule below), fasting plasma glucose should be used to determine the therapeutic response to Glucophage or Glucophage XR and identify the minimum effective dose for the patient. Thereafter, glycosylated hemoglobin should be measured at intervals of approximately 3 months. The therapeutic goal should be to decrease both fasting plasma glucose and glycosylated hemoglobin levels to normal or near normal by using the lowest effective dose of Glucophage or Glucophage XR, either when used as monotherapy or in combination with sulfonylurea or insulin.
Monitoring of blood glucose and glycosylated hemoglobin will also permit detection of primary failure, i.e., inadequate lowering of blood glucose at the maximum recommended dose of medication, and secondary failure, i.e., loss of an adequate blood glucose lowering response after an initial period of effectiveness.
Short-term administration of Glucophage or Glucophage XR may be sufficient during periods of transient loss of control in patients usually well-controlled on diet alone.
Glucophage XR tablets must be swallowed whole and never crushed or chewed. Occasionally, the inactive ingredients of Glucophage XR will be eliminated in the feces as a soft, hydrated mass.
Recommended Dosing Schedule
In general, clinically significant responses are not seen at doses below 1500 mg per day. However, a lower recommended starting dose and gradually increased dosage is advised to minimize gastrointestinal symptoms.
The usual starting dose of Glucophage (metformin hydrochloride) Tablets is 500 mg twice a day or 850 mg once a day, given with meals. Dosage increases should be made in increments of 500 mg weekly or 850 mg every 2 weeks, up to a total of 2000 mg per day, given in divided doses. Patients can also be titrated from 500 mg twice a day to 850 mg twice a day after 2 weeks. For those patients requiring additional glycemic control, Glucophage may be given to a maximum daily dose of 2550 mg per day. Doses above 2000 mg may be better tolerated given 3 times a day with meals.
The usual starting dose of Glucophage XR (metformin hydrochloride) Extended-Release Tablets is 500 mg once daily with the evening meal. Dosage increases should be made in increments of 500 mg weekly, up to a maximum of 2000 mg once daily with the evening meal. If glycemic control is not achieved on Glucophage XR 2000 mg once daily, a trial of Glucophage XR 1000 mg twice daily should be considered. If higher doses of metformin are required, Glucophage should be used at total daily doses up to 2550 mg administered in divided daily doses, as described above. (See CLINICAL PHARMACOLOGY: Clinical Studies.)
In a randomized trial, patients currently treated with Glucophage were switched to Glucophage XR. Results of this trial suggest that patients receiving Glucophage treatment may be safely switched to Glucophage XR once daily at the same total daily dose, up to 2000 mg once daily. Following a switch from Glucophage to Glucophage XR, glycemic control should be closely monitored and dosage adjustments made accordingly (see CLINICAL PHARMACOLOGY: Clinical Studies).
The usual starting dose of Glucophage is 500 mg twice a day, given with meals. Dosage increases should be made in increments of 500 mg weekly up to a maximum of 2000 mg per day, given in divided doses. Safety and effectiveness of Glucophage XR in pediatric patients have not been established.
Transfer From Other Antidiabetic Therapy
When transferring patients from standard oral hypoglycemic agents other than chlorpropamide to Glucophage or Glucophage XR, no transition period generally is necessary. When transferring patients from chlorpropamide, care should be exercised during the first 2 weeks because of the prolonged retention of chlorpropamide in the body, leading to overlapping drug effects and possible hypoglycemia.
Concomitant Glucophage or Glucophage XR and Oral Sulfonylurea Therapy in Adult Patients
If patients have not responded to 4 weeks of the maximum dose of Glucophage or Glucophage XR monotherapy, consideration should be given to gradual addition of an oral sulfonylurea while continuing Glucophage or Glucophage XR at the maximum dose, even if prior primary or secondary failure to a sulfonylurea has occurred. Clinical and pharmacokinetic drug-drug interaction data are currently available only for metformin plus glyburide (glibenclamide).
With concomitant Glucophage or Glucophage XR and sulfonylurea therapy, the desired control of blood glucose may be obtained by adjusting the dose of each drug. In a clinical trial of patients with type 2 diabetes and prior failure on glyburide, patients started on Glucophage 500 mg and glyburide 20 mg were titrated to 1000/20 mg, 1500/20 mg, 2000/20 mg, or 2500/20 mg of Glucophage and glyburide, respectively, to reach the goal of glycemic control as measured by FPG, HbA1c, and plasma glucose response (see CLINICAL PHARMACOLOGY: Clinical Studies). However, attempts should be made to identify the minimum effective dose of each drug to achieve this goal. With concomitant Glucophage or Glucophage XR and sulfonylurea therapy, the risk of hypoglycemia associated with sulfonylurea therapy continues and may be increased. Appropriate precautions should be taken. (See Package Insert of the respective sulfonylurea.)
If patients have not satisfactorily responded to 1 to 3 months of concomitant therapy with the maximum dose of Glucophage or Glucophage XR and the maximum dose of an oral sulfonylurea, consider therapeutic alternatives including switching to insulin with or without Glucophage or Glucophage XR.
Concomitant Glucophage or Glucophage XR and Insulin Therapy in Adult Patients
The current insulin dose should be continued upon initiation of Glucophage or Glucophage XR therapy. Glucophage or Glucophage XR therapy should be initiated at 500 mg once daily in patients on insulin therapy. For patients not responding adequately, the dose of Glucophage or Glucophage XR should be increased by 500 mg after approximately 1 week and by 500 mg every week thereafter until adequate glycemic control is achieved. The maximum recommended daily dose is 2500 mg for Glucophage and 2000 mg for Glucophage XR. It is recommended that the insulin dose be decreased by 10% to 25% when fasting plasma glucose concentrations decrease to less than 120 mg/dL in patients receiving concomitant insulin and Glucophage or Glucophage XR. Further adjustment should be individualized based on glucose-lowering response.
Specific Patient Populations
Glucophage or Glucophage XR are not recommended for use in pregnancy. Glucophage is not recommended in patients below the age of 10 years. Glucophage XR is not recommended in pediatric patients (below the age of 17 years).
The initial and maintenance dosing of Glucophage or Glucophage XR should be conservative in patients with advanced age, due to the potential for decreased renal function in this population. Any dosage adjustment should be based on a careful assessment of renal function. Generally, elderly, debilitated, and malnourished patients should not be titrated to the maximum dose of Glucophage or Glucophage XR.
Monitoring of renal function is necessary to aid in prevention of lactic acidosis, particularly in the elderly. (See WARNINGS.)
Glucophage® (metformin hydrochloride) Tablets
|500 mg||Bottles of 100||NDC 0087-6060-05|
|500 mg||Bottles of 500||NDC 0087-6060-10|
|850 mg||Bottles of 100||NDC 0087-6070-05|
|1000 mg||Bottles of 100||NDC 0087-6071-11|
Glucophage 500 mg tablets are round, white to off-white, film-coated tablets debossed with "BMS 6060" around the periphery of the tablet on one side and "500" debossed across the face of the other side.
Glucophage 850 mg tablets are round, white to off-white, film-coated tablets debossed with "BMS 6070" around the periphery of the tablet on one side and "850" debossed across the face of the other side.
Glucophage 1000 mg tablets are white, oval, biconvex, film-coated tablets with "BMS 6071" debossed on one side and "1000" debossed on the opposite side and with a bisect line on both sides.
Glucophage® XR (metformin hydrochloride) Extended-Release Tablets
|500 mg||Bottles of 100||NDC 0087-6063-13|
|750 mg||Bottles of 100||NDC 0087-6064-13|
Glucophage XR 500 mg tablets are white to off-white, capsule shaped, biconvex tablets, with "BMS 6063" debossed on one side and "500" debossed across the face of the other side.
Glucophage XR 750 mg tablets are capsule shaped, biconvex tablets, with "BMS 6064" debossed on one side and "750" debossed on the other side. The tablets are pale red and may have a mottled appearance.
Store at 20°-25° C (68°-77° F); excursions permitted to 15°-30° C (59°-86° F). [See USP Controlled Room Temperature.]
Dispense in light-resistant containers.
Glucophage® is a registered trademark of Merck SantÃ© S.A.S., an associate of Merck KGaA of Darmstadt, Germany. Licensed to Bristol-Myers Squibb Company.
Bristol-Myers Squibb Company
Princeton, NJ 08543 USA
last update: 01/2009
Glucohage, metformin hydrochloride, patient information (in plain English)
The information in this monograph is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects. This information is generalized and is not intended as specific medical advice. If you have questions about the medicines you are taking or would like more information, check with your doctor, pharmacist, or nurse.
back to: Browse all Medications for Diabetes
Staff, H. (2009, January 29). Glucophage for Treatment of Diabetes - Glucophage Full Prescribing Information, HealthyPlace. Retrieved on 2022, December 4 from https://www.healthyplace.com/diabetes/medications/glucophage-glucophage-xr-side-effects